Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can weekly tests pinpoint when STIs are truly gone?

NCT ID NCT06216964

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study follows 140 adults who have been treated for uncomplicated chlamydia or gonorrhea infections. Participants will have weekly swabs or urine tests to check when the bacteria's genetic material (RNA) disappears from the body, up to 4 weeks after starting treatment. The goal is to understand how quickly these infections clear at different body sites, such as the genitals, throat, or rectum, which could help guide future testing and care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Weekly NAAT (PCR) diagnostic tests after treatment
What this could lead to
If successful, this could help doctors know when it's safe to assume an infection is cleared, potentially reducing unnecessary follow-up tests and anxiety.
What could go wrong
This is an observational study, not a treatment trial, so it won't change how infections are treated. Results may vary by infection site and may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Apr 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Patients attending the Trait d'Union department at the Nouvel Hôpital Civil for PrEP consultations, AES or HIV infection. * Over 18 years of age * Male or female * Who have had an uncomplicated CT and/or NG infection treated with currently recommended therapies (Ceftriaxone 500mg DU for NG infections, Doxycycline 200mg per day for 1 week for rectal CT infections and Azithromycin 1g DU or Doxycycline 7 days for other CT infections). * Subject affiliated to a social health insurance scheme * Subject able to understand the aims and risks of the research and to give dated and signed informed consent Exclusion Criteria: * \- Complicated CT and/or NG infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, Fiessinger-Leroy-reiter syndrome, Fitz-Hugh-Curtis syndrome). * Interfering treatments and associated diseases: Severe immunosuppression (HIV infection with CD4 less than 200/mm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant. * Impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.). * Subject under court protection * Subject under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chlamydia trachomatis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chlamydia trachomatis infectious disease gonorrhea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chlamydia trachomatis Neisseria gonorrhoeae Uncomplicated infections

Contacts and locations

Locations

  • Service du Trait d'Union

    Strasbourg, France, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.